Company news
PolyPid Ltd. news in 2025
PolyPid Ltd.'s news releases, calls and decks from 2025, newest first.
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
December 16, 2025
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission
December 3, 2025
PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025
November 25, 2025
PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results
November 12, 2025
PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"
November 6, 2025
PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025
October 29, 2025
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress
September 30, 2025
PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference
September 17, 2025
PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀
September 16, 2025
PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
September 3, 2025
PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference
September 2, 2025
Investor Presentation (3e767d)
August 14, 2025
PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results
August 13, 2025
PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer
August 12, 2025
PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025
July 30, 2025
PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market
July 15, 2025
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
June 16, 2025
PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints
June 9, 2025
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
June 6, 2025
PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
May 20, 2025
PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 14, 2025
PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025
April 29, 2025
PolyPid to Participate in The Citizens Life Sciences Conference
April 22, 2025
PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
March 11, 2025
PolyPid to Participate in the 37th Annual ROTH Conference
March 3, 2025
PolyPid Ltd. to Present at the Q1 Investor Summit Virtual Conference on March 11th, 2025
February 26, 2025
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
February 11, 2025
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
January 29, 2025
PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025
January 28, 2025
Calls in 2025
Decks in 2025
- Technical Presentation (June 2025)
Technical · 12 slides · Jun 9, 2025